Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer's Disease

被引:24
|
作者
Wang, Jun [1 ,3 ]
Zhao, Zhong [1 ]
Lin, Emi [2 ]
Zhao, Wei [1 ]
Qian, Xianjuan [1 ]
Freire, Daniel [1 ]
Bilski, Amanda E. [1 ]
Cheng, Alice [1 ]
Vempati, Prashant [1 ]
Ho, Lap [1 ,3 ]
Ono, Kenjiro [4 ]
Yamada, Masahito [4 ]
Pasinetti, Giulio M. [1 ,3 ]
机构
[1] Mt Sinai Sch Med, Dept Neurol, New York, NY USA
[2] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA
[3] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, New York, NY USA
[4] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa, Japan
来源
PLOS ONE | 2013年 / 8卷 / 06期
基金
美国国家卫生研究院;
关键词
AMYLOID-BETA-PROTEIN; ANTIHYPERTENSIVE-MEDICATION-USE; MOUSE MODEL; SYNAPTIC PLASTICITY; NATURAL OLIGOMERS; MEMORY; A-BETA(1-42); PREVENTION; DEMENTIA; THERAPY;
D O I
10.1371/journal.pone.0065232
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Alzheimer's disease (AD) is rapidly becoming one of the leading causes of disability and mortality in the elderly. As life-expectancy increases, an increasing number of people will rely on modern medicines to treat age-associated disorders. Among these medications, some might benefit, while others might exacerbate, the pathogenesis of AD. We screened 1,600 FDA approved drugs for beta-amyloid (A beta)-modifying activity and identified drugs that can potentially influence amyloid precursor protein processing. In this study, we focused on cardiovascular drugs and demonstrated that some hypertensive medication can differentially modulate A beta, both in vitro and in vivo. Our study suggests that some commonly prescribed drugs might exert unintended effects and modulate AD and provides the basis for continuing investigation of the role of individual drugs on a case-by-case basis. This line of investigation will lead to the identification of common medications that are potentially beneficial or detrimental to AD as a reference for physicians to consider when prescribing the most appropriate drugs for their patients, particularly for treating chronic disorders among the growing geriatric population.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Side-effects and drugs for Alzheimer's disease
    Schück, S
    Bentué-Ferrer, D
    Beaufils, C
    Polard, E
    Belliard, S
    Allain, H
    THERAPIE, 1999, 54 (02): : 237 - 242
  • [12] Therapeutic Effects of Natural Drugs on Alzheimer's Disease
    Ma, Yuan
    Yang, Man-wen
    Li, Xin-wei
    Yue, Jian-wei
    Chen, Jun-zong
    Yang, Mei-wen
    Huang, Xuan
    Zhu, Lian-lian
    Hong, Fen-fang
    Yang, Shu-long
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [13] Chemically Tailoring Cardiovascular Drugs for Alzheimer's Disease Drug Discovery
    Pasinetti, Giulio
    Ho, Lap
    Ono, Kenjiro
    Wang, Jun
    CIRCULATION RESEARCH, 2012, 111 (04)
  • [15] Development of cardiovascular β-amyloid lowering drugs as a treatment in Alzheimer's disease
    Pasinetti, Giulio M.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S39 - S39
  • [16] Drugs for Alzheimer's disease
    Winblad, B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 3 - 3
  • [17] Drugs for Alzheimer's disease
    Ritter, James M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (04) : 501 - 503
  • [18] Risk factors for cardiovascular events of antidementia drugs in Alzheimer's disease patients
    Hernandez, Inmaculada
    JOURNAL OF CLINICAL GERONTOLOGY & GERIATRICS, 2016, 7 (03): : 77 - 82
  • [19] Molecular pathogenesis of Alzheimer's disease
    Iwatsubo, T
    INTERNAL MEDICINE, 2003, 42 (03) : 312 - 312
  • [20] Mitochondria in Alzheimer's Disease Pathogenesis
    Reiss, Allison B.
    Gulkarov, Shelly
    Jacob, Benna
    Srivastava, Ankita
    Pinkhasov, Aaron
    Gomolin, Irving H.
    Stecker, Mark M.
    Wisniewski, Thomas
    De Leon, Joshua
    LIFE-BASEL, 2024, 14 (02):